Tonix Pharmaceuticals has announced that it will acquire assets from Trigemina, Inc that include intranasal oxytocin for the treatment of migraine headaches. Trigemina had licensed the nasal spray, now called TNX-1900, from Stanford University, and Tonix will assume that license. Trigemina Chief Medical Officer Shashidar H. Kori said, “We are excited that Tonix … [Read more...] about Tonix Pharmaceuticals acquires intranasal oxytocin from Trigemina
Business
Vectura and Aerami partner on development of inhaled imatinib for PAH
Inhalation CDMO Vectura and inhaled drug developer Aerami Therapeutics (formerly Dance Biopharm) have signed an agreement for development of inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH), the companies said. Aerami will pay nothing up front, but will make milestone payments and pay development fees and royalties on any sales. Aerami will … [Read more...] about Vectura and Aerami partner on development of inhaled imatinib for PAH
United Therapeutics alleges that Liquidia has infringed on its Tyvaso patents
United Therapeutics has filed a patent infringement suit against Liquidia Technologies in the US District Court for the District of Delaware alleging infringement of US patents 9,604,901 and 9,593,066, which protect Tyvaso treprostinil inhalation solution. Both patents are titled "Process to prepare treprostinil, the active ingredient in Remodulin" and both expire … [Read more...] about United Therapeutics alleges that Liquidia has infringed on its Tyvaso patents
UCB acquires Engage Therapeutics, Staccato alprazolam
UCB said that it is paying $125 million up front, plus up to $145 million in potential milestone payments, to acquire Engage Therapeutics. Engage has a single candidate, Staccato inhaled alprazolam, which is in Phase 2 development for the treatment of epileptic seizures. Engage acquired Staccato alprazolam from Alexza in 2017, and UCB says that it will continue to … [Read more...] about UCB acquires Engage Therapeutics, Staccato alprazolam
Marinomed announces upcoming launches of its nasal sprays in Italy and Austria
Marinomed Biotech has announced that Fidia Farmaceutici will begin marketing Marinomed's Carragelose-based nasal sprays in Italy in Fall 2020, and Sanova Pharma has signed an agreement to launch the new Carravin nasal spray in Austria in 2021, subject to approval. The company's Carregelose products are already available in a number of European countries, as well as … [Read more...] about Marinomed announces upcoming launches of its nasal sprays in Italy and Austria
Phase 2a trial of Novus’s OP0201 nasal MDI for otitis media fails to meet primary endpoints
Novus Therapeutics said that a Phase 2a clinical trial of its OP0201 intranasal surfactant MDI for the treatment of acute otitis media in infants and children failed to meet its primary endpoints of "resolution of bulging tympanic membrane at visit 2 and resolution of middle ear effusion at visit 3." The study did show greater resolution of middle ear effusion for … [Read more...] about Phase 2a trial of Novus’s OP0201 nasal MDI for otitis media fails to meet primary endpoints
Atossa Therapeutics announces development of intranasal therapy for mild COVID-19
Atossa Therapeutics announced that it has signed an agreement with Summit Biosciences for development and manufacturing of an intranasal formulation of Atossa's AT-301 as a candidate for the treatment of mild COVID-19, and it plans to submit an IND for clinical trials expected to begin in the third quarter of this year. The company said it is also investigating the … [Read more...] about Atossa Therapeutics announces development of intranasal therapy for mild COVID-19
CARB-X and CF Foundation award Microbion grants worth up to $17 million for development of inhaled pravisbismane
Microbion Corporation said that it has received a grant worth up to $11.5 million from global non-profit CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and a grant worth up to $5.6 million from the Cystic Fibrosis Foundation (CFF) for pre-clinical and Phase 1 development of its pravibismane inhalation suspension for the treatment of … [Read more...] about CARB-X and CF Foundation award Microbion grants worth up to $17 million for development of inhaled pravisbismane
Teva Canada imports supply of UK-branded salbutamol (albuterol) MDIs under interim order
Teva Canada said that it has imported a 4-week supply of Salamol salbutamol (albuterol) sulfate MDIs through Teva UK under an interim order by the Minister of Health in response to shortages of the inhalers in Canada caused by the COVID-19 pandemic. Salamol MDIs are marketed by IVAX Pharmaceuticals in the UK; Teva acquired IVAX in 2006. Health Canada recently … [Read more...] about Teva Canada imports supply of UK-branded salbutamol (albuterol) MDIs under interim order
Senzer to develop inhaled antivirals for the treatment of COVID-19
Senzer Pharmaceuticals has announced the launch of a new Critical Care Division for development of two inhaled anti-viral drugs for the treatment of COVID-19. The company did not specify which drugs it planned to develop but did say that the formulations would be delivered via MDI rather than with its SIDD (Systemic Inhaled Delivery Device), which is used for its … [Read more...] about Senzer to develop inhaled antivirals for the treatment of COVID-19